3-(2,3-二氢-1,4-苯并二氧杂环己-6-基)丙酰胺 | 858789-85-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并二恶烷
• 中文名称: 3-(2,3-二氢-1,4-苯并二氧杂环己-6-基)丙酰胺
• 英文名称: 3-(2,3-dihydro-benzo[1,4]dioxin-6-yl)-propionic acid amide
• 英文别名: 3-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-propionsaeure-amid；3-(2,3-Dihydro-1,4-benzodioxin-6-yl)propanamide
• CAS: 858789-85-2
• 化学式: C₁₁H₁₃NO₃
• mdl: MFCD11939366
• 分子量: 207.229
• InChiKey: ZUVHWYSWQHRFEB-UHFFFAOYSA-N

物化性质

• 熔点：
  117 °C
• 沸点：
  428.5±34.0 °C(Predicted)
• 密度：
  1.230±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.363
• 拓扑面积：
  61.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-(2,3-二氢-1,4-苯并二氧杂环己-6-基)丙酰胺 在 sodium hypobromide 作用下， 生成 2-(2,3-二氢-1,4-苯并二氧杂环己-6-基)乙胺盐酸盐
  参考文献：
  名称：

  Synthetische Versuche in der Isochinolinreihe I

  摘要：

  DOI：

  10.1007/bf01044198
• 作为产物：
  描述：

  3-(2,3-二氢-1,4-苯并二氧)丙酸 生成 3-(2,3-二氢-1,4-苯并二氧杂环己-6-基)丙酰胺
  参考文献：
  名称：

  Synthetische Versuche in der Isochinolinreihe I

  摘要：

  DOI：

  10.1007/bf01044198

文献信息

• NOVEL COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS
  申请人：Pesyan Amir

  公开号：US20110046138A1

  公开（公告）日：2011-02-24

  A series of novel compounds showing anticonvulsant activity is described. Such pharmaceutically active compounds may also show utility in the treatment of other central nervous system (“CNS”) diseases and disorders, such as anxiety, depression, insomnia, migraine headaches, schizophrenia, Parkinson's disease, spasticity, Alzheimer's disease, and bipolar disorder. Furthermore, such compounds may additionally find utility as analgesics (e.g., for the treatment of chronic or neuropathic pain) and as neuroprotective agents useful in the treatment of stroke(s), chronic neurodegenerative diseases (such as Alzheimer's disease and Huntington's disease), and/or traumatic brain and/or spinal cord injuries. Moreover, these/such compounds may also be useful in the treatment of status epilepticus and/or as chemical countermeasures.

  本文描述了一系列具有抗癫痫活性的新化合物。这些药物活性化合物也可能在治疗其他中枢神经系统（“CNS”）疾病和障碍方面具有用途，例如焦虑、抑郁、失眠、偏头痛、精神分裂症、帕金森病、痉挛、阿尔茨海默病和躁郁症。此外，这些化合物还可能作为镇痛剂（例如，用于治疗慢性或神经性疼痛）和作为神经保护剂在中风、慢性神经退行性疾病（如阿尔茨海默病和亨廷顿病）以及/或创伤性脑和/或脊髓损伤的治疗中有用。此外，这些化合物还可能在治疗癫痫持续状态和/或作为化学对策方面有用。
• ISOQUINOLINES AS IGF-1R INHIBITORS
  申请人：Analytecon S.A.

  公开号：EP1931636A1

  公开（公告）日：2008-06-18
• SMALL MOLECULE REGULATORS OF MITOCHONDRIAL FUSION AND METHODS OF USE THEREOF
  申请人：Washington University

  公开号：US20200281899A1

  公开（公告）日：2020-09-10

  Compositions comprising small molecule mitofusin agonists are described. The mitofusin modulating agents are useful for treating diseases or disorders associated with a mitochondria-associated disease, disorder, or condition such as diseases or disorders associated with mitofusin 1 (Mfn1) and/or mitofusin 2 (Mfn2), or mitochondrial dysfunction. Methods of treatment, pharmaceutical formulations, and screening methods for identifying compounds that regulate mitochondrial function are also described.
• [EN] ISOQUINOLINES AS IGF-1R INHIBITORS<br/>[FR] ISOQUINOLINES UTILISES EN TANT QU'INHIBITEURS D'IGF-1R
  申请人：ANALYTECON SA

  公开号：WO2007029106A1

  公开（公告）日：2007-03-15

  [EN] Compounds of the formula (I) were synthesized. They were found to down- regulate or inhibit the expression or function of the IGF-I receptor.
  [FR] On a synthétisé des composés ayant la formule (I). On a découvert que ces composés régulent vers le bas ou inhibent l'expression ou la fonction du récepteur IGF-1.
• Synthetische Versuche in der Isochinolinreihe I
  作者：A. Dobrowsky

  DOI：10.1007/bf01044198

  日期：——